A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality

Medical Decision Making

Volumn 38, Issue 1_suppl, 2018, Pages 78S-88S

  Huang, Xuelin ^a   Li, Yisheng ^a   Song, Juhee ^a   Berry, Donald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adjuvant treatments; approximate Bayesian computation; Bayesian simulation; beyond stage shift; breast cancer; cancer screening; mammography

Indexed keywords

ESTROGEN RECEPTOR;

ADJUVANT CHEMOTHERAPY; BAYES THEOREM; BREAST TUMOR; CANCER CENTER; COMPUTER SIMULATION; DIAGNOSTIC IMAGING; FEMALE; HEALTH SERVICE; HUMAN; MAMMOGRAPHY; MORTALITY; PROCEDURES; PROTO ONCOGENE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TEXAS; TREATMENT OUTCOME; UNITED STATES;

BAYES THEOREM; BREAST NEOPLASMS; CANCER CARE FACILITIES; CHEMOTHERAPY, ADJUVANT; COMPUTER SIMULATION; FEMALE; GENES, ERBB-2; HUMANS; MAMMOGRAPHY; MEDICAL OVERUSE; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SURVIVAL ANALYSIS; TEXAS; TREATMENT OUTCOME; UNITED STATES;

EID: 85040587865     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X17714473     Document Type: Article

References (36)

1. Alagoz O, Berry D, Feuer EJ. Introduction to the cancer intervention and surveillance modeling network (CISNET) breast cancer models. Med Decis Making. 2018;38(1S):3–8.
2. Mandelblatt JS, Near AM, Miglioretti DL. Common model inputs in collaborative breast cancer modeling. Med Decis Making. 2018;38(1S):9–23.
3. Jackson H, Vanness D, Stout NK. Contribution of breast cancer to overall mortality for US women. Med Decis Making. 2018;38(1S):24–31.
4. Lee SJ, Li X, Huang H. The Dana-Farber CISNET model for breast cancer screening strategies: An update. Med Decis Making. 2018;38(1S):44–53.
5. van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning H. Simulating the impact of risk-based screening and treatment on breast cancer outcomes with MISCAN-Fadia. Med Decis Making. 2018;38(1S):54–65.
6. Schechter CB, Near AM, Jayasekera J, Chang Y, Mandelblatt JS. Structure, function, and applications of the Georgetown-Einstein (GE) breast cancer simulation model. Med Decis Making. 2018;38(1S):66–77.
7. van den Broek JJ, Nicolien T., van Ravesteyn NT. Comparing CISNET breast cancer models using the maximum clinical incidence reduction methodology. Med Decis Making. 2018;38(1S):112–125.
8. Alagoz Oguzhan Ergun MA. The University of Wisconsin breast cancer epidemiology simulation model: An update. Med Decis Making. 2018;38(1S):99–111.
9. van den Broek JJ, van Ravesteyn NT, Cevik M. Comparing CISNET breast cancer models using the maximum clinical incidence reduction methodology. Med Decis Making. 2018;38(1S):112–125.
10. van Ravesteyn NT, van den Broek JJ, Li X. Modeling ductal carcinoma in situ (DCIS) an overview of CISNET model approaches. Med Decis Making. 2018;38(1S):126–139.
11. Berry DA, Cronin KA, Plevritis SK. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.
12. Berry DA. Statistics: a Bayesian Perspective. Belmont (CA): Duxbury Press; 1996.
13. Berry DA, Stangl DK. Bayesian Biostatistics. New York (NY): Marcel Dekker; 1996.
14. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. London (UK): John Wiley & Sons; 2004.
15. Tanner MA. Tools for Statistical Inference: Methods for the Exploration of Posterior Distributions and Likelihood Functions. 3rd ed.New York (NY): Springer; 1996.
16. Berry DA, Inoue L, Shen Y. Modeling the impact of treatment and screening on U.S. breast cancer mortality: A Bayesian approach. J Natl Cancer Inst Monogr. 2006;36:30–6.
17. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005;97:1195–203.
18. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2015 Sub (1973- 2013) (Katrina/Rita Population Adjustment) -Linked to County Attributes - Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April2016, based on the November2015 submission.
19. Chlebowski RT, Hendrix SL, Langer RD. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women the Women’s Health Initiative Randomized Trial. J Am Med Assoc. 2003;289:3243–53.
20. Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr. 2006;36:7–15.
21. Rosenberg MA. Competing risks to breast cancer mortality. J Natl Cancer Inst Monogr. 2006;36:15–9.
22. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006;36:19–25.
23. Cronin KA, Mariotto AB, Clarke LD, Feuer EJ. Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. J Natl Cancer Inst Monogr. 2006;36:26–9.
24. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hor- monal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:16871717.
25. Woods & Poole Economics, Inc. 2001 Regional Database: Estimated July 1 population by race, sex and single year and 5-year age groups based on 1990 Census and post-censual Census Bureau estimates. Available at: https://www.woodsandpoole.com/.
26. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th edition. Philadelphia, PA: Lippincott Raven Publishers; 2002.
27. Shapiro S, Venet W, Strax P, Venet L. Periodic screening for breast cancer: The Health Insurance Plan Project and its sequelae, 1963-1986. Baltimore (MD): Johns Hopkins University Press; 1988.
28. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J. 1992;147:1459–76.
29. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study 2: Breast cancer detection and death rates among women aged 50 to 59 years. Can Med Assoc J. 1992;147:1477–88.
30. Cronin KA, Yu B, Kraphcho M. Modeling the dissemination of mammography in the United States. Cancer Causes Control. 2005;16:701–12.
31. Hakkama M, Holli K, Isola J. Aggressiveness of screen-detected breast cancers. Lancet. 1995;345:221–4.
32. Frisell J, Eklund G, Hellstrom L, Somell A. Analysis of interval breast carcinomas in a randomized screening trial in Stockholm. Breast Cancer Res Treat. 1987;9:219–25.
33. Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst. 2002;94:1626–34.
34. Mandelblatt JS, Stout NK, Schechter CB. Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies. Ann Int Med. 2016;164:215–25.
35. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L. Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet. 2006;368:2053–60.
36. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years’ follow-up: a randomised controlled trial. Lancet Oncol. 2015;16:1123–32.